<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362294</url>
  </required_header>
  <id_info>
    <org_study_id>PPMS-GA Depot 002</org_study_id>
    <nct_id>NCT03362294</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS</brief_title>
  <official_title>A Prospective, Multicenter, Two Arms, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 25 mg or 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mapi Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mapi Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IIa study with GA Depot in subjects with Primary Progressive MS. GA Depot&#xD;
      will be administered intramuscularly (IM), once every four weeks for 148 weeks.&#xD;
&#xD;
      The purpose of this study is to assess the safety and efficacy of GA Depot to slow the&#xD;
      accumulation of disability progression in subjects with Primary Progressive MS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  30 Subjects with a diagnosis of primary progressive multiple sclerosis (PPMS) who are&#xD;
           not treated for PPMS at study entry (except for symptoms relief).&#xD;
&#xD;
        -  Study product is GA long-acting injection (GA Depot) which is a combination of&#xD;
           extended-release microspheres for injection and diluent (water for injection) for&#xD;
           parenteral use. GA Depot will be administered intramuscularly (IM).&#xD;
&#xD;
        -  The study duration for an individual subject in the core study will be 156 weeks,&#xD;
           consisting of 4 weeks of screening evaluation (weeks -4 to 0), followed by a 148-week&#xD;
           open-label treatment period, and a 4 weeks follow up period: through a total of 41&#xD;
           visits.&#xD;
&#xD;
        -  Vital signs and safety assessment will be performed at each visit during the study.&#xD;
&#xD;
        -  Physical examination will be performed at screening, baseline, 1 week after the second&#xD;
           GA Depot treatment, 3 months after first GA Depot treatment and every 3 months&#xD;
           thereafter. Last physical examination will be performed at FU visit.&#xD;
&#xD;
        -  MRI will be performed at screenings and every 6 months thereafter until the end of the&#xD;
           treatment period .&#xD;
&#xD;
        -  Safety laboratory tests will be performed at screening, baseline, 1 month after first&#xD;
           treatment, and every 3 months thereafter.&#xD;
&#xD;
        -  Neurological assessment will be performed at screening, baseline, 3 months, and then&#xD;
           every 3 months until end of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The first 20 subjects are allocated to the 40mg arm and the last 10 subjects are allocated to the 25mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Adverse Events and Injection Site Reactions)</measure>
    <time_frame>152 weeks</time_frame>
    <description>Assessment of Adverse events (AEs) &amp; Injection Sites Reactions (ISRs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Confirmed Disease Progression)</measure>
    <time_frame>148 weeks</time_frame>
    <description>Time to onset of Confirmed Disease Progression (CDP) assessed by Expanded Disability Status Scale (EDSS). EDSS is a method of quantifying disability in people with MS. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Whole brain volume change)</measure>
    <time_frame>148 weeks</time_frame>
    <description>MRI assessment of percent of whole brain volume change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Cortical volume change)</measure>
    <time_frame>148 weeks</time_frame>
    <description>MRI assessment of percent of cortical volume change.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>GA Depot 40mg once monthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA Depot 25mg once monthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IM injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GA Depot 40mg once monthly</intervention_name>
    <description>Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)</description>
    <arm_group_label>GA Depot 40mg once monthly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GA Depot 25mg once monthly</intervention_name>
    <description>Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)</description>
    <arm_group_label>GA Depot 25mg once monthly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects diagnosed with PPMS; Diagnosis of PPMS consistent with the&#xD;
             McDonald Criteria (revisions of 2010).&#xD;
&#xD;
          2. Age between 18 and 65 years (inclusive).&#xD;
&#xD;
          3. Subjects diagnosed with PPMS for at least 1 year and with signs of disease progression&#xD;
             in the year prior to screening, in a rate of ≥ 1 point increase / year in the EDSS&#xD;
             score for EDSS between 2-5 and a rate of ≥0.5 point increase / year in the EDSS scores&#xD;
             &gt; 5.&#xD;
&#xD;
          4. EDSS ≥2 and ≤ 6.5 (Pyramidal or Cerebellar FS ≥ 2).&#xD;
&#xD;
          5. Documented history or the presence at screening of &gt; 1 oligoclonal band (OCB) if&#xD;
             quantitative testing was done, or OCB+ if not quantitative testing done and/or&#xD;
             positive IgG index in the cerebrospinal fluid (CSF).&#xD;
&#xD;
          6. Women of child bearing potential must have a negative urine pregnancy test at&#xD;
             screening and use an adequate contraceptive method throughout the study.&#xD;
&#xD;
          7. Ability to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with RRMS, SPMS, or PRMS.&#xD;
&#xD;
          2. Subjects with a documented history of clinical relapse events.&#xD;
&#xD;
          3. Any relevant medical, surgical, or psychiatric condition, laboratory value, or&#xD;
             concomitant medication which, in the opinion of the investigator, makes the subject&#xD;
             unsuitable for study entry or potentially unable to complete all aspects of the study.&#xD;
&#xD;
          4. Contraindications or inability to successfully undergo magnetic resonance imaging&#xD;
             (MRI) scanning.&#xD;
&#xD;
          5. Subjects diagnosed with any other than MS systemic autoimmune disease that may impact&#xD;
             the CNS with MS like lesions such as Sarcoidosis, Sjögren's syndrome, Systemic Lupus&#xD;
             Erythematosus (SLE), Lyme disease, APLA syndrome, etc.. Subjects with stable&#xD;
             local/organ autoimmune disease such as psoriasis, Cutaneous Lupus erythematosus,&#xD;
             thyroiditis (Hashimoto, grave) etc. may be considered eligible upon the PI's&#xD;
             discretion.&#xD;
&#xD;
          6. Severe anemia (hemoglobin &lt;10 g/dL).&#xD;
&#xD;
          7. Abnormal renal function (serum creatinine &gt;1.5xULN or creatinine clearance &lt;30&#xD;
             ml/min).&#xD;
&#xD;
          8. Abnormal liver function (transaminases &gt;2xULN).&#xD;
&#xD;
          9. Pregnant or breast-feeding women.&#xD;
&#xD;
         10. Treatment with any kind of steroids during the last month prior to screening visit.&#xD;
&#xD;
         11. History of any anaphylactic reaction and/or serious allergic reaction following a&#xD;
             vaccination, a known hypersensitivity to any component of the study drug, e.g.&#xD;
             glatiramer acetate (GA), polylactic-co-glycolic acid (PLGA), polyvinyl alcohol (PVA).&#xD;
&#xD;
         12. Known or suspected history of drug or alcohol abuse.&#xD;
&#xD;
         13. Known as positive for HIV, hepatitis, VDRL, or tuberculosis.&#xD;
&#xD;
         14. Active malignant disease of any kind. However, a patient, who had a malignant disease&#xD;
             in the past, was treated and is currently disease - free for at least 7 years, may be&#xD;
             considered eligible, upon the PI and sponsor's discretion.&#xD;
&#xD;
         15. Previous treatment with B-cell-targeting therapies (e.g. rituximab, ocrelizumab,&#xD;
             atacicept, belimumab or ofatumumab) within 6 months prior to screening visit.&#xD;
&#xD;
         16. Previous treatment with cladribine within 2 years prior to screening visit&#xD;
&#xD;
         17. Previous treatment with azathioprine, mitoxantrone or methotrexate within 6 months&#xD;
             prior to screening visit.&#xD;
&#xD;
         18. Previous treatment with lymphocyte-trafficking modifiers (e.g. natalizumab,&#xD;
             fingolimod) within 6 months prior to screening visit. Subjects should have a total&#xD;
             lymphocyte count within normal range.&#xD;
&#xD;
         19. Previous treatment with beta interferons, intravenous immunoglobulin, plasmapheresis&#xD;
             within 2 months prior to screening visit.&#xD;
&#xD;
         20. Previous treatment with any glatiramer acetate therapy within 3 months prior to&#xD;
             screening visit.&#xD;
&#xD;
         21. Uncontrolled diabetes.&#xD;
&#xD;
         22. Participation in an investigational study drug within 30 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Karni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coordinating PI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mapi Pharma Research site 09</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Afanasiev</last_name>
      <phone>+972 4 7771926</phone>
      <email>s_afanasiev@rmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mapi Pharma Research site 07</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Dambinsky</last_name>
      <phone>02-6777716</phone>
      <email>keidy@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mapi Pharma Research site 08</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaniv Rodity</last_name>
      <phone>03-6528734</phone>
      <email>yar@clalait.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mapi Pharma Research site 06</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiran Rogof</last_name>
      <phone>08-9441364</phone>
      <email>shiranro1@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mapi Pharma Research site 01</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Komarov</last_name>
      <phone>03-6974380</phone>
      <email>irinako@tlvmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mapi Pharma Research site 20</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihail Gavriliuc, MD</last_name>
      <phone>+37322205383</phone>
      <email>mgavriliuc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mapi Pharma Research site 22</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olesea Odainic, MD</last_name>
      <phone>+37379443354</phone>
      <email>oodainic@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Moldova, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

